This article is more than 5 years old. Information may no longer be current.
Takeda: Study revealed no increased bladder cancer risk with Actos
Click Here to Manage Email Alerts
Results of the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a multi-database retrospective matched cohort study for pioglitazone containing medications, including Actos, with up to 10 years follow-up have recently been released, according to a press release from Takeda Pharmaceutical Company Limited.
“Actos is an important treatment option for patients with type 2 diabetes,” Alfonzo Perez, MD, vice president of clinical research at Takeda, said in the release. “These data further reinforce the positive benefit/risk profile for Actos. These long-term studies underscore Takeda’s commitment to ensuring physicians have the best available information to make treatment decisions.”
The results revealed no association between pioglitazone and the risk for bladder cancer (HR = 0.99; 95% CI, 0.75-1.3), consistent with findings from another study conducted by the University of Pennsylvania and Division of Research at Kaiser Permanente Northern California, also demonstrating no increased risk for bladder cancer in ever users of pioglitazone (HR = 1.06; 95% CI, 0.89-1.26).
Results of Takeda’s study further revealed a decreased mortality risk with ever use of pioglitazone (HR = 0.67; 95% CI, 0.64-0.7).
“Patient safety remains a top priority for Takeda,” Perez said. “Throughout a product’s lifecycle we continue to monitor and conduct additional research to further our knowledge. This milestone is an important example of Takeda’s commitment to conducting further research and sharing the outcomes with regulatory agencies, physicians and others.”